A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.

医学 德诺苏马布 前列腺癌 临床终点 不利影响 骨痛 内科学 乳腺癌 随机对照试验 骨转移 骨质疏松症 肿瘤科 泌尿科 癌症
作者
Mark Clemons,Michael Ong,Carol Stober,D. Scott Ernst,Christopher M. Booth,Christina M. Canil,Mihaela Mates,Andrew Robinson,Phillip S. Blanchette,Anil A. Joy,John Hilton,Olexiy Aseyev,Gregory R. Pond,Brian Hutton,Ahwon Jeong,Lisa Vandermeer,Dean Fergusson
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:37 (15_suppl): 11501-11501 被引量:11
标识
DOI:10.1200/jco.2019.37.15_suppl.11501
摘要

11501 Background: Defining the optimal dosing interval of commonly used bone-targeted agents (BTAs), such as denosumab and bisphosphonates, for patients with bone metastases remains an important clinical question. We performed a pragmatic randomised trial comparing the non-inferiority of 12- versus 4-weekly BTAs in patients with bone metastases from breast and prostate cancer. Methods: Patients with bone metastases, who were either BTA-naïve, or already receiving, denosumab, pamidronate or zoledronate were eligible. They were randomised to receive their chosen BTA every 12- or 4-weeks for one year. The primary endpoint was Health related quality of life (HRQL) (EORTC-QLQ-C30 Functional Domain - Physical Subdomain). Secondary endpoints included: pain (EORTC-QLQ-BM22 - pain domain), Global Health Status (EORTC-QLQ-C30), symptomatic skeletal events (SSE) rates and time to SSEs. Adverse events and toxicity profiles were also compared. Results: Of 263 patients (60.8% breast and 39.2% prostate), 130 (49.4%) were randomised to 12-weekly and 133 (50.6%) to 4-weekly therapy. 138 (52.5%) were bone-agent naïve. The BTAs included; denosumab (n=148, 56.3%), zoledronate (n=63, 24.0%) and pamidronate (n=52, 19.8%). Study-reported outcomes showed no significant difference in; HRQL-physical domain (median [range]: 0 [-86, 40] vs. 0 [-66, 53.3]), pain (median [range]: 0 [-66, 72] vs. 0 [-100, 88]), Global Health Status (median [range]: 0 [-100, 66.7] vs. 0 [-83, 33.3]), SSE rates (N [%]: 24 [18.5%] vs. 22 [16.5%]), 1-year SSE-free rate (median, range; 73.2% [63.6, 80.7] vs. 77.9% [69.1, 84.4]) between the 12- and 4-weekly arms, respectively. Subgroup analyses for BTA naïve and pre-treated patients, and for patients receiving denosumab, zoledronate and pamidronate, showed no significant difference between the 12- and 4-weekly arms. There was no significant difference in reported rates of renal impairment (2.3% vs. 3.0%), symptomatic hypocalcaemia (1.5% vs. 1.5%) or osteonecrosis of the jaw (0.8% vs. 0.8%). Conclusion: The findings of this trial are consistent with those previously reported for de-escalating zoledronate. This trial also included patients receiving de-escalated denosumab and pamidronate. While the results of the Swiss REDUSE trial are awaited, the data presented would suggest that de-escalation of all commonly used BTAs is a reasonable treatment option. Clinical trial information: NCT02721433.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汤绮菱完成签到,获得积分10
刚刚
1秒前
英姑应助ding采纳,获得10
1秒前
dd完成签到,获得积分10
3秒前
领导范儿应助niekyang采纳,获得10
3秒前
Fashioner8351完成签到,获得积分10
3秒前
Leslie完成签到 ,获得积分10
3秒前
Zo完成签到,获得积分10
4秒前
闪闪的夏之完成签到,获得积分10
6秒前
小初发布了新的文献求助10
7秒前
知非完成签到 ,获得积分10
7秒前
漫漫楚威风完成签到,获得积分10
9秒前
英俊的铭应助暮晓见采纳,获得10
9秒前
科研通AI2S应助luckweb采纳,获得10
10秒前
flymove完成签到,获得积分10
11秒前
威武的初兰完成签到 ,获得积分10
11秒前
英俊的铭应助枫叶的脚步采纳,获得10
12秒前
陈昇发布了新的文献求助30
12秒前
思睿拜完成签到 ,获得积分10
13秒前
15秒前
斯文败类应助小初采纳,获得10
16秒前
lhlgood完成签到,获得积分10
17秒前
齐天完成签到 ,获得积分10
20秒前
21秒前
暮晓见发布了新的文献求助10
22秒前
RayLam完成签到,获得积分10
23秒前
园艺小学生完成签到,获得积分10
24秒前
共享精神应助栗子味采纳,获得10
25秒前
小初完成签到,获得积分20
25秒前
musei发布了新的文献求助10
27秒前
Hello应助牧谷采纳,获得10
28秒前
28秒前
30秒前
小猪猪饲养员完成签到,获得积分10
32秒前
33秒前
33秒前
lxlcx完成签到,获得积分10
33秒前
cc完成签到 ,获得积分10
34秒前
科研通AI5应助youyouG采纳,获得30
35秒前
小星星完成签到,获得积分10
36秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571455
求助须知:如何正确求助?哪些是违规求助? 3142008
关于积分的说明 9445318
捐赠科研通 2843544
什么是DOI,文献DOI怎么找? 1562861
邀请新用户注册赠送积分活动 731368
科研通“疑难数据库(出版商)”最低求助积分说明 718541